department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Leqembi Iqlik · pharmadog

pharmadog
drugs
Leqembi Iqlik

drug · antibody

patient view →

lecanemab

Marketedupdated 2mo ago

by Eisai Co Ltd🔗 ChEMBL

Approved

annual revenue · 2024–2024peak $231M

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for 3 indications.

indications

investigational

Alzheimer's Disease

targets

Amyloid-beta precursor protein

all catalysts(8)

approval · 8

view all 8 catalysts →

News(0)

no news has mentioned this drug yet

brand

Leqembi Iqlik

trade names

Leqembi

generic

lecanemab-irmb

MOA

Amyloid-beta A4 protein inhibitor

indication

Alzheimer's Disease

phase

marketed

approved

2023-01-06

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 2

drugLEQEMBI32 co-mentions · 8 sources
tagApproval32 co-mentions · 8 sources

Trials studying lecanemab

phase3A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Diseaseactive not recruitingn=1,906
phase3AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloidactive not recruitingn=1,400
phase3DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Diseaseactive not recruitingn=40
phase2A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Diseasecompletedn=856
phase3Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001active not recruitingn=490
phase3Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)active not recruitingn=197
phase2A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Diseaseactive not recruitingn=105
EP1Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapyactive not recruitingn=15

more trials →